| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
123,030,000 |
| Market
Cap: |
17.71(B) |
| Last
Volume: |
477,045 |
Avg
Vol: |
726,924 |
| 52
Week Range: |
$143.71 - $212.05 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 824 |
| Guru Rank Value : 0.5 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Alnylam Pharmaceuticals is a commercial-stage biopharmaceutical company developing therapeutics based on RNA interference. Co. has four RNAi-based medicines, ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO™ (lumasiran) and Leqvio® (inclisiran). ONPATTRO is approved for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. GIVLAARI is approved for the treatment of adults with acute hepatic porphyria. Co. has approval for OXLUMO for the treatment of hyperoxaluria type 1 (PH1) in all age groups. Leqvio (inclisiran) is being developed for the treatment of adults with hypercholesterolemia or mixed dyslipidemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
46,855 |
76,855 |
102,504 |
247,093 |
| Total Sell Value |
$7,107,715 |
$12,957,715 |
$17,713,340 |
$48,829,179 |
| Total People Sold |
6 |
7 |
8 |
9 |
| Total Sell Transactions |
11 |
12 |
18 |
35 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Maraganore John |
Chief Executive Officer |
• • – |
2020-02-20 |
4 |
OE |
$9.14 |
$317,752 |
D/D |
34,765 |
224,758 |
|
- |
|
| Sharp Philip A |
Director |
– • – |
2020-02-12 |
4 |
AS |
$130.00 |
$3,900,000 |
D/D |
(30,000) |
235,633 |
|
13% |
|
| Sharp Philip A |
Director |
– • – |
2020-02-12 |
4 |
OE |
$9.14 |
$374,400 |
D/D |
30,000 |
265,633 |
|
- |
|
| Greenstreet Yvonne |
Chief Operating Officer |
• – – |
2020-02-10 |
4 |
AS |
$130.00 |
$1,285,960 |
D/D |
(9,892) |
1,916 |
|
20% |
|
| Greenstreet Yvonne |
Chief Operating Officer |
• – – |
2020-02-10 |
4 |
OE |
$42.22 |
$236,432 |
D/D |
5,600 |
11,808 |
|
- |
|
| Paul Steven M |
Director |
– • – |
2020-02-10 |
4 |
AS |
$130.00 |
$3,900,000 |
D/D |
(30,000) |
1,000 |
|
20% |
|
| Paul Steven M |
Director |
– • – |
2020-02-10 |
4 |
OE |
$14.67 |
$440,100 |
D/D |
30,000 |
31,000 |
|
- |
|
| Keating Laurie |
EVP, Chief Legal Officer |
• – – |
2020-02-10 |
4 |
AS |
$129.00 |
$1,290,000 |
D/D |
(10,000) |
12,258 |
|
20% |
|
| Keating Laurie |
EVP, Chief Legal Officer |
• – – |
2020-02-10 |
4 |
OE |
$77.40 |
$774,000 |
D/D |
10,000 |
22,258 |
|
- |
|
| Greenstreet Yvonne |
Chief Operating Officer |
• – – |
2020-02-07 |
4 |
AS |
$123.90 |
$774,375 |
D/D |
(6,250) |
6,208 |
|
13% |
|
| Greenstreet Yvonne |
Chief Operating Officer |
• – – |
2020-02-07 |
4 |
OE |
$42.22 |
$263,875 |
D/D |
6,250 |
12,458 |
|
- |
|
| Vaishnaw Akshay |
President, R&D |
• – – |
2020-02-07 |
4 |
AS |
$125.00 |
$2,963,500 |
D/D |
(23,708) |
11,215 |
|
13% |
|
| Vaishnaw Akshay |
President, R&D |
• – – |
2020-02-07 |
4 |
OE |
$42.22 |
$960,505 |
D/D |
22,750 |
34,923 |
|
- |
|
| Keating Laurie |
EVP, Chief Legal Officer |
• – – |
2020-01-29 |
4 |
AS |
$119.00 |
$754,103 |
D/D |
(6,337) |
8,595 |
|
13% |
|
| Keating Laurie |
EVP, Chief Legal Officer |
• – – |
2020-01-29 |
4 |
OE |
$77.40 |
$490,484 |
D/D |
6,337 |
14,932 |
|
- |
|
| Keating Laurie |
EVP, Chief Legal Officer |
• – – |
2020-01-27 |
4/A |
OE |
$77.40 |
$283,516 |
D/D |
3,663 |
12,258 |
|
- |
|
| Keating Laurie |
EVP, Chief Legal Officer |
• – – |
2020-01-27 |
4 |
AS |
$115.55 |
$4,829,970 |
D/D |
(41,037) |
8,595 |
|
8% |
|
| Keating Laurie |
EVP, Chief Legal Officer |
• – – |
2020-01-27 |
4 |
OE |
$42.22 |
$1,451,270 |
D/D |
34,374 |
49,632 |
|
- |
|
| Poulton Jeffrey V. |
Chief Financial Officer |
• – – |
2020-01-03 |
4 |
A |
$0.00 |
$0 |
I/I |
19 |
19 |
|
- |
|
| Greenstreet Yvonne |
Chief Operating Officer |
• – – |
2019-12-12 |
4 |
D |
$120.61 |
$386,917 |
D/D |
(3,208) |
6,208 |
|
- |
|
| Greenstreet Yvonne |
Chief Operating Officer |
• – – |
2019-12-12 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
9,416 |
|
- |
|
| Greenstreet Yvonne |
Chief Operating Officer |
• – – |
2019-11-20 |
4 |
AS |
$105.00 |
$882,420 |
D/D |
(8,404) |
1,916 |
|
- |
|
| Greenstreet Yvonne |
Chief Operating Officer |
• – – |
2019-11-20 |
4 |
OE |
$42.22 |
$354,817 |
D/D |
8,404 |
10,320 |
|
- |
|
| Fanucci Marsha |
Director |
– • – |
2019-11-20 |
4 |
AS |
$100.00 |
$7,500,000 |
D/D |
(75,000) |
0 |
|
- |
|
| Fanucci Marsha |
Director |
– • – |
2019-11-20 |
4 |
OE |
$9.14 |
$1,035,000 |
D/D |
75,000 |
75,000 |
|
- |
|
475 Records found
|
|
Page 9 of 19 |
|
|
3.41 (2.31%) 
